These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 4072726)
1. Are schizophrenics with abnormal dexamethasone suppression test results a distinct subgroup? Dewan MJ; Pandurangi AK; Levy BF; Boucher ML; Major LF Acta Psychiatr Scand; 1985 Sep; 72(3):274-7. PubMed ID: 4072726 [TBL] [Abstract][Full Text] [Related]
2. A comprehensive study of chronic schizophrenic patients. II: Biological, neuropsychological, and clinical correlates of CT abnormality. Pandurangi AK; Dewan MJ; Boucher M; Levy B; Ramachandran T; Bartell K; Bick PA; Phelps BH; Major L Acta Psychiatr Scand; 1986 Feb; 73(2):161-71. PubMed ID: 3705993 [TBL] [Abstract][Full Text] [Related]
5. Plasma DBH, platelet MAO and proteins of red blood cell membranes in individuals with variants of the normal EEG. Propping P; Friedl W; Nebel B; Feige A Neuropsychobiology; 1979; 5(6):309-16. PubMed ID: 503304 [TBL] [Abstract][Full Text] [Related]
6. Comparison of MAO, D beta H, and COMT activities in chronic schizophrenics selected on the basis of nailfold capillary pattern. Dunlop SR; Sattin A; Shea P; Hendrie HC Acta Psychiatr Scand; 1981 Nov; 64(5):409-14. PubMed ID: 7347105 [TBL] [Abstract][Full Text] [Related]
7. Dexamethasone suppression test in severe schizophrenic illness: effects of plasma dexamethasone and caffeine levels. Holsboer-Trachsler E; Buol C; Wiedemann K; Holsboer F Acta Psychiatr Scand; 1987 Jun; 75(6):608-13. PubMed ID: 3618283 [TBL] [Abstract][Full Text] [Related]
8. [Determination of dopamine-beta-hydroxylase (DBH) and monoamine oxidase (MAO) activities in platelets and plasma in schizophrenic, maniac-depressive and neurotic patients]. Xavier Vieira R; Azevedo M; Polónio P; Manso C Acta Med Port; 1986; 7(1):45-8. PubMed ID: 3728081 [No Abstract] [Full Text] [Related]
9. Platelet 5-HT and plasma cortisol concentrations after dexamethasone suppression test in patients with different time course of schizophrenia. Jakovljević M; Mück-Seler D; Pivac N; Crncević Z Neuropsychobiology; 1998; 37(3):142-5. PubMed ID: 9597670 [TBL] [Abstract][Full Text] [Related]
10. Does the dexamethasone suppression test have clinical utility in psychiatry? Baldessarini RJ; Arana GW J Clin Psychiatry; 1985 Feb; 46(2 Pt 2):25-9. PubMed ID: 3968053 [TBL] [Abstract][Full Text] [Related]
12. The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Yeragani VK Can J Psychiatry; 1990 Mar; 35(2):128-32. PubMed ID: 2138504 [TBL] [Abstract][Full Text] [Related]
13. Relative utility of three indices of neuropsychological impairment in a young, chronic schizophrenic population. Boucher ML; Dewan MJ; Donnelly MP; Pandurangi AK; Bartell K; Diamond T; Major LF J Nerv Ment Dis; 1986 Jan; 174(1):44-6. PubMed ID: 3941309 [TBL] [Abstract][Full Text] [Related]
14. Negative symptoms of schizophrenia and the dexamethasone suppression test. Garyfallos G; Lavrentiadis G; Amoutzias D; Monas K; Manos N Acta Psychiatr Scand; 1993 Dec; 88(6):425-8. PubMed ID: 8310850 [TBL] [Abstract][Full Text] [Related]
15. Dexamethasone suppression test in schizophrenia: its relation to monoamine metabolism in hypothalamic-pituitary-adrenal axis. Kaneko M; Murata S; Hoshino Y; Takahagi K; Yokoyama F; Watanabe M; Kumashiro H Neuropsychobiology; 1990-1991; 24(1):12-6. PubMed ID: 2132636 [TBL] [Abstract][Full Text] [Related]
16. Serum DBH and platelet MAO in patients with depressive disorders. Honecker H; Fähndrich E; Coper H; Helmchen H Pharmacopsychiatria; 1981 Jan; 14(1 Suppl):10-4. PubMed ID: 7248043 [TBL] [Abstract][Full Text] [Related]
17. Platelet monoamine oxidase and plasma dopamine-beta-hydroxylase activities in patients with multiple sclerosis. Markianos M; Sfagos C; Bistolaki E Acta Neurol Scand; 1991 Dec; 84(6):531-3. PubMed ID: 1792858 [TBL] [Abstract][Full Text] [Related]